• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Surface Modifications of Influenza Proteins Upon Virus Inactivation by Beta-Propiolactone

tetano

Editor, Senior Moderator
Proteomics. 2013 Oct 7. doi: 10.1002/pmic.201300096. [Epub ahead of print]
Surface Modifications of Influenza Proteins Upon Virus Inactivation by Beta-Propiolactone.
She YM, Cheng K, Farnsworth A, Li X, Cyr TD.
Source

Centre for Vaccine Evaluation, Biologics and Genetic Therapies Directorate, Health Canada, Ottawa, Ontario, Canada.
Abstract

Inactivation of intact influenza viruses using formaldehyde or beta-propiolactone is essential for vaccine production and safety. The extent of chemical modifications of such reagents on viral proteins needs to be extensively investigated to better control the reactions and quality of vaccines. We have evaluated the effect of beta-propiolactone inactivation on two candidate re-assortant vaccines (NIBRG-121xp and NYMC-X181A) derived from A/California/07/2009 pandemic influenza viruses using high-resolution Fourier transform ion cyclotron mass spectrometry-based proteomic approaches. We report here a UPLC MS/MS method for determining full-length protein sequences of hemagglutinin and neuraminidase through protein delipidation, various enzymatic digestions, and subsequent mass spectrometric analyses of the proteolytic peptides. We also demonstrate the ability to reliably identify hundreds of unique sites modified by propiolactone on the surface of glycoprotein antigens. The location of these modifications correlated in changes to protein folding, conformation and stability, but demonstrated no effect on protein disulfide linkages. In some cases, these modifications resulted in suppression of protein function, an effect that correlated with the degree of change of the modified amino acids' side chain length and polarity. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.
KEYWORDS:

Influenza vaccine, Mass spectrometry, Post-translational modification, Virus inactivation, beta-propiolactone

PMID:
24123778
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24123778
 
Back
Top Bottom